Incidence of bcr‑abl fusion transcripts in healthy individuals

Ismail,Said I.; Naffa,Randa G.; Yousef,Al‑Motassem F.; Ghanim,Majd T.

doi:10.3892/mmr.2014.1951

Incidence of bcr‑abl fusion transcripts in healthy individuals

Authors:
- Said I. Ismail
- Randa G. Naffa
- Al‑Motassem F. Yousef
- Majd T. Ghanim
View Affiliations

Affiliations: Molecular Biology Research Laboratory, Department of Biochemistry, Faculty of Medicine, University of Jordan, Amman 11942, Jordan, Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, University of Jordan, Amman 11942, Jordan
Published online on: February 13, 2014 https://doi.org/10.3892/mmr.2014.1951
Pages: 1271-1276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bcr‑abl fusion transcripts, resulting from translocation t(9;22), are hallmarks of Philadelphia chromosome positive (Ph+) leukemias. This translocation is detected in >90% of patients with chronic myelogenous leukemia and ~20% of acute lymphoblastic leukemia patients, which predominantly express the p210 and p190 proteins, respectively. Although the occurrence of t(9;22) in healthy individuals has been previously demonstrated, the number of studies is limited and the results are inconsistent. The present study screened for the presence of bcr‑abl transcripts in the blood of a group of healthy individuals using a sensitive‑nested reverse transcription polymerase chain reaction (RT‑PCR) assay. Samples were collected from 189 healthy volunteers (145 adults and 44 children). RNA was reverse transcribed and amplified by two rounds of PCR, amplifying the two common variants of bcr‑abl transcripts, p190 and p210. While the bcr‑abl p190 transcript was not detected, the p210 transcript was detected in ~10% of samples. Notably, the incidence of p210 translocation was higher in males (12.2%) compared with females (7.7%) and males were 2.4 times more likely to have the translocation. A significant incidence was also observed in adults compared with children, where adults were 6 times more likely to have the translocation. The presence of bcr‑abl transcripts in the blood of a significant proportion of healthy individuals should be considered in long‑term investigations to establish its exact association with the risk of developing leukemia. Furthermore, the current assays should be revised to consider the proportion of normal samples carrying the p210 transcripts when making a differential diagnosis.

View Figures

View References

1	Avery A: Molecular diagnostics of hematologic malignancies. Top Companion Anim Med. 24:144–150. 2009. View Article : Google Scholar : PubMed/NCBI
2	Nowell PC and Hungerford DA: Chromosome studies in human leukemia. IV Myeloproliferative syndrome and other atypical myeloid disorders. J Natl Cancer Inst. 29:911–931. 1962.PubMed/NCBI
3	Chen Y, Peng C, Li D and Li S: Molecular and cellular bases of chronic myeloid leukemia. Protein Cell. 1:124–132. 2010. View Article : Google Scholar : PubMed/NCBI
4	Laurent E, Talpaz M, Kantarjian H and Kurzrock R: The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res. 61:2343–2355. 2001.PubMed/NCBI
5	Kurzrock R, Kantarjian HM, Druker BJ and Talpaz M: Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 138:819–830. 2003. View Article : Google Scholar : PubMed/NCBI
6	Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88:2375–2384. 1996.PubMed/NCBI
7	Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F and Rotoli B: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 88:2410–2414. 1996.PubMed/NCBI
8	Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR and Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 36:93–99. 1984. View Article : Google Scholar : PubMed/NCBI
9	Heisterkamp N, Knoppel E and Groffen J: The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia. Nucleic Acids Res. 16:10069–10081. 1998. View Article : Google Scholar : PubMed/NCBI
10	Shtivelman E, Lifshitz B, Gale RP, Roe BA and Canaani E: Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 47:277–284. 1986. View Article : Google Scholar : PubMed/NCBI
11	Woodring PJ, Hunter T and Wang JY: Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci. 116:2613–2626. 2003. View Article : Google Scholar : PubMed/NCBI
12	Li S, Couvillon AD, Brasher BB and Van Etten RA: Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J. 20:6793–6804. 2001. View Article : Google Scholar : PubMed/NCBI
13	Rumpold H and Webersinke G: Molecular pathogenesis of philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL? Curr Cancer Drug Targets. 11:3–19. 2011. View Article : Google Scholar : PubMed/NCBI
14	Janz S, Potter M and Rabkin CS: Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer. 36:211–223. 2003. View Article : Google Scholar : PubMed/NCBI
15	Song J, Mercer D, Hu X, Liu H and Li MM: Common leukemia- and lymphoma-associated genetic aberrations in healthy individuals. J Mol Diagn. 13:213–219. 2011. View Article : Google Scholar : PubMed/NCBI
16	Cross NC, Melo JV, Feng L and Goldman JM: An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 8:186–189. 1994.PubMed/NCBI
17	Nogva HK, Evensen SA and Madshus IH: One-tube multiplex RT-PCR of BCR-ABL transcripts in analysis of patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia. Scand J Clin Lab Invest. 58:647–654. 1998. View Article : Google Scholar : PubMed/NCBI
18	Kaneda R, Toyota M, Yamashita Y, Koinuma K, Choi YL, Ota J, Kisanuki H, Ishikawa M, Takada S, Shimada K and Mano H: High-throughput screening of genome fragments bound to differentially acetylated histones. Genes Cells. 9:1167–1174. 2004. View Article : Google Scholar : PubMed/NCBI
19	Okamoto K, Karasawa M, Sakai H, Ogura H, Morita K and Naruse T: A novel acute lymphoid leukemia type BCR/ABL transcript in chronic myelogenous leukemia. Br J Haematol. 96:611–613. 1997. View Article : Google Scholar : PubMed/NCBI
20	Lichty B, Keating A, Callum J, Yee K, Croxford R, Corpus G, Nwachukwu B, Kim P, Guo J and Kamel-Reid S: Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukemia. Br J Haematol. 103:711–715. 1998. View Article : Google Scholar : PubMed/NCBI
21	Biernaux C, Loos M, Sels A, Huez G and Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 86:3118–3122. 1995.PubMed/NCBI
22	Bose S, Deininger M, Gora-Tybor J, Goldman JM and Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 92:3362–3367. 1998.
23	Daley GQ, Van Etten RA and Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:824–830. 1990. View Article : Google Scholar : PubMed/NCBI
24	Kelliher MA, McLaughlin J, Witte ON and Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA. 87:6649–6653. 1990. View Article : Google Scholar : PubMed/NCBI
25	Elefanty AG and Cory S: Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions. Mol Cell Biol. 12:1755–1763. 1992.PubMed/NCBI
26	Bäsecke J, Griesinger F, Trümper L and Brittinger G: Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol. 81:64–75. 2002.
27	Ren R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 5:172–183. 2005. View Article : Google Scholar : PubMed/NCBI
28	Rusakiewicz S, Madrigal A, Travers P and Dodi AI: BCR/ABL- specific CD8⁺ T cells can be detected from CML patients, but are only expanded from healthy donors. Cancer Immunol Immunother. 58:1449–1457. 2009.PubMed/NCBI
29	Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GM, D’Amaro J, Oudshoorn M, et al: HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood. 93:3863–3865. 1999.PubMed/NCBI